v3.22.2.2
Revenue Recognition
 9 Months Ended
Oct. 01, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition REVENUE RECOGNITION
Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations(1) (in millions):
Three Months EndedNine Months Ended
October 1, 2022October 2, 2021October 1, 2022October 2, 2021
U.S.$716.1 $657.4 $2,116.7 $1,859.0 
Europe(2)
365.1 334.5 1,098.8 1,037.6 
All other countries(3)
19.0 50.8 80.8 137.2 
Total net sales$1,100.2 $1,042.7 $3,296.3 $3,033.8 

(1) The net sales by geographic locations is derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $6.2 million and $20.1 million for the three and nine months ended October 1, 2022, respectively, and $7.6 million and $17.4 million for the three and nine months ended October 2, 2021, respectively.
(3) Includes net sales generated primarily in Mexico, Australia and Canada.

Product Category
        
As a result of the completed acquisition of HRA Pharma, the Company updated its global reporting product categories beginning in the second quarter of 2022. These product category updates have been adjusted retrospectively to reflect the changes. The following updates have no impact on the Company's historical consolidated financial position, results of operations, or cash flows:
•The creation of a new "Women's Health" reporting category, comprised of the women's health portfolio of HRA Pharma, in addition to legacy Perrigo women's health products;
•The creation of a new "Skin Care" reporting category, comprised of all of the products in the legacy Perrigo "Skincare and Personal Hygiene" category, except for legacy Perrigo women's health products, and the skin care products of HRA Pharma; and
•The "Other" category in the CSCI segment now includes the HRA Pharma Rare Diseases business.

The following is a summary of our net sales by category (in millions):
Three Months EndedNine Months Ended
October 1, 2022October 2, 2021October 1, 2022October 2, 2021
CSCA(1)
Upper Respiratory$132.2 $121.9 $430.9 $345.8 
Nutrition124.4 105.3 376.7 293.3 
Digestive Health119.6 110.6 363.3 344.0 
Pain and Sleep-Aids104.0 108.4 309.5 292.9 
Oral Care83.6 76.7 230.6 227.4 
Healthy Lifestyle73.8 72.1 208.7 213.0 
Skin Care48.9 46.4 138.4 139.1 
Women's Health12.4 10.4 32.6 28.7 
Vitamins, Minerals, and Supplements ("VMS")7.1 8.1 23.0 24.3 
Other CSCA(2)
16.3 34.3 46.5 48.5 
Total CSCA722.3 694.2 2,160.2 1,957.0 
CSCI
Skin Care132.4 114.2 342.1 304.3 
Upper Respiratory63.2 52.3 184.6 137.4 
VMS45.9 54.6 146.1 171.2 
Pain and Sleep-Aids29.0 33.7 130.8 131.4 
Healthy Lifestyle25.0 37.1 105.4 134.5 
Women's Health29.9 13.4 67.3 42.1 
Oral Care20.2 23.1 65.1 70.6 
Digestive Health4.1 5.7 13.3 15.5 
Other CSCI(3)
28.2 14.4 81.4 69.8 
Total CSCI377.9 348.5 1,136.1 1,076.8 
Total net sales$1,100.2 $1,042.7 $3,296.3 $3,033.8 
(1) Includes net sales from our OTC contract manufacturing business.
(2) Consists primarily of product sales and royalty income related to supply and distribution agreements, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3) Consists primarily of liquid licensed products, our distribution business, rare disease products, and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized over time. Customer contracts recognized over time exist predominately in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $102.2 million and $270.6 million for the three and nine months ended October 1, 2022, respectively, and $80.8 million and $213.7 million for the three and nine months ended October 2, 2021, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment over time; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):
Balance Sheet LocationOctober 1, 2022December 31, 2021
Short-term contract assetsPrepaid expenses and other current assets$31.8 $40.2